Cantor Fitzgerald Issues Negative Forecast for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Bicycle Therapeutics in a report released on Thursday, May 8th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($3.87) per share for the year, down from their prior estimate of ($3.49). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The firm had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%.

Other equities analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 2nd. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the company an “equal weight” rating in a research report on Monday, May 5th. Royal Bank of Canada lowered their price target on Bicycle Therapeutics from $35.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Barclays decreased their price objective on Bicycle Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, May 1st. Finally, B. Riley reduced their price target on Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Bicycle Therapeutics Stock Up 3.1%

Shares of Bicycle Therapeutics stock opened at $8.60 on Monday. The company has a market cap of $595.14 million, a PE ratio of -2.61 and a beta of 1.60. The business has a 50 day moving average price of $8.41 and a 200-day moving average price of $13.57. Bicycle Therapeutics has a 52 week low of $6.10 and a 52 week high of $28.67.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. increased its holdings in Bicycle Therapeutics by 406.2% in the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock worth $63,769,000 after buying an additional 3,655,101 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Bicycle Therapeutics by 15.8% in the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company’s stock worth $152,395,000 after purchasing an additional 1,485,397 shares during the last quarter. Fcpm Iii Services B.V. increased its holdings in shares of Bicycle Therapeutics by 47.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock worth $48,333,000 after purchasing an additional 1,112,369 shares during the last quarter. Long Focus Capital Management LLC purchased a new position in Bicycle Therapeutics in the fourth quarter worth about $7,603,000. Finally, Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics in the third quarter worth about $10,028,000. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.